阿替普酶与巴曲酶治疗急性脑梗死的临床效果及血清学指标

Clinical Comparison of Alteplase and Bacitracin in the Treatment of Acute Cerebral Infarction

目的对比阿替普酶与巴曲酶治疗急性脑梗死(ACI)的临床效果。方法选取商丘市第四人民医院收治的ACI患者78例,按随机数字表法分为对照组、观察组,各39例。对照组采用巴曲酶静脉溶栓,观察组采用阿替普酶静脉溶栓,两组在此基础上均行对症支持治疗。治疗7 d后,比较两组临床疗效、日常生活活动能力、血清学指标及不良反应发生情况。结果两组治疗前Barthel指数、TNF-α、NSE水平比较,差异无统计学意义(P>0.05);观察组治疗后Barthel指数高于对照组,TNF-α、NSE水平低于对照组,差异有统计学意义(P<0.05)。观察组临床总有效率为92.31%,高于对照组的74.36%,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论阿替普酶治疗ACI的临床疗效好于巴曲酶,能够有效减轻患者神经功能损伤,改善血清学指标与自理能力,且具有较高的安全性。

Objective To compare the clinical effects of Alteplase and Batroxobin in the treatment of acute cerebral infarction(ACI).Methods 78 ACI patients in Fourth People's Hospital of Shangqiu City were randomly divided into control group and observation group,39 cases in each group.The control group received intravenous thrombolysis with Batroxobin,and the observation group received intravenous thrombolysis with Alteplase.On this basis,both groups received symptomatic support treatment.After 7 days of treatment,the clinical efficacy,activities of daily living(ADL),serological indicators and the incidence of adverse reactions of the two groups were compared.Results There were no significant differences in Barthel index,TNF-αand NSE levels between the two groups before treatment(P>0.05).After treatment,the Barthel index in the observation group was higher than that in the control group,while the level of TNF-αand NSE was lower than that of the control group(P<0.05).The total clinical effective rate of the observation group was 92.31%,higher than that of the control group(74.36%)(P<0.05).There was no statistical difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Ateplase is more effective than Batroxobin in the treatment of ACI,which can effectively reduce the neurological damage of patients,improve the serological indicators and self-care ability,and has higher safety.